GCM
GILD icon

Genus Capital Management’s Gilead Sciences GILD Stock Holding History

Genus Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-191,100
Closed -$17.7M – 257
2024
Q4 		$17.7M Buy
191,100
+112,460
+143% +$10.1M 2.4% 3
2024
Q3 		$6.59M Buy
+78,640
New +$6M 0.86% 38
2024
Q1 		– Sell
-108,065
Closed -$8.75M – 278
2023
Q4 		$8.75M Buy
+108,065
New +$8.41M 1.28% 22

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Genus Capital Management's GILD Position: Q2 2026 in Review

Genus Capital Management reduced its Gilead Sciences (GILD) stake by 60% in Q2 2026, selling an estimated $9.38M and leaving 48,067 shares worth $6.07M. The position accounts for 0.6% of the portfolio, ranked #51.

Genus Capital Management first reported a position in GILD in Q2 2023 and has held it in 8 quarters since. The position peaked at $20.6M in Q1 2025. 2,287 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Genus Capital Management held 48,067 shares of Gilead Sciences worth $6.07M as of Q2 2026.
  • Genus Capital Management sold 71,213 Gilead Sciences shares in Q2 2026, an estimated $9.38M.
  • Gilead Sciences made up 0.6% of Genus Capital Management's portfolio in Q2 2026, its #51 holding.
  • Genus Capital Management first reported a position in Gilead Sciences in Q2 2023 and has held it in 8 quarters since.
  • Genus Capital Management's Gilead Sciences position peaked at $20.6M in Q1 2025.
  • 2,287 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Genus Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.